The combined experience to date with DLI suggests that only a minority of patients with myeloma (probably less than 15%) will experience long-term benefit from current approaches to its application, and this must be balanced against the morbidity associated with chronic GvHD. However, it does provide optimism for the possibility of the development of more refined, antigen-specific strategies. All of our responding patients had conversion to multilineage full donor chimerism (assessed by means of polymerase chain reaction analysis of informative minisatellite regions (short tandem repeat (STR) loci)), suggesting that allogeneic rather than tumor-specific targets may be important in mediating responses. This suggestion is supported by the crossreactivity of cytotoxic T-cell clones derived following DLI with both normal and malignant host cells, 7 but does not exclude the coincident development of separate populations mediating GvM and GvHD activity. Indeed, other investigators have isolated and characterised apparently tumorspecific CD8 þ T-cell clones in patients with relapsed myeloma responding to DLI.
8 Attempts at donor vaccination against patient idiotype in order to selectively enhance GvM activity have been limited by the generation of mainly CD4 þ T-cell responses, but advances in DNA vaccine generation now allow this issue to be readdressed. Further knowledge of the mechanisms of response both in terms of effectors and their targets, and of the mechanisms of subsequent immune evasion will likely be required to translate initial optimism into therapeutic reality for patients with myeloma. 2 They also confirm the close association of response with development of GvHD as well as the higher incidence of GvHD in recipients of unrelated grafts even at such low donor lymphocyte infusion (DLI) doses. These results are comparable to those observed after full intensity allografting. Our data with low-dose DLI did show a lower risk of GvHD compared to other studies with higher doses.
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In the series of Peggs and Mackinnon, only two out of the 10 responding patients had not progressed after a median follow-up of 636 days after DLI. In our series, eight out of 21 patients showed response to DLI. Of the three complete responders, one has relapsed while the other two remain in CR after a follow-up of 721 and 658 days after DLI. The first patient has until now not developed any signs of GvHD, the second patient developed limited chronic GvHD. Interestingly, one partial responder and one patient with stable disease at the time of our last report are now in complete response without any further treatment. The patient in stable disease (positive immunofixation) converted negative in May 2003 and later on developed extensive chronic GvHD in September 2003. He remains in CR now 596 days after DLI. The patient who was in PR with diminishing serum immunoglobulin level at the time of our last report developed limited chronic GvHD and went on to convert negative in the immunofixation in April 2003. She remains in CR 645 days after DLI. Two patients in PR died, one of severe acute GvHD 2 and the other of infectious complications. The remaining two patients in PR have experienced progressive disease requiring further treatment.
Although our follow-up is not as long as in the series of Peggs and Mackinnon (1215 days in the surviving patients) or in another recent follow-up after full intensity allografts, 3 our observations do indicate that durable responses may also be achieved in a subset of patients responding with CR to DLI after RIC allografts. A recent study by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) revealed that molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival. 4 It may therefore mean that the degree of remission achieved after DLI and not the kind of conditioning regimen preceding allografting would determine the durability of response. We have reported two cases of DLI-induced molecular remissions in myeloma patients.
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RIC allografting provides the foundation for adoptive immunotherapy with DLI. In a bid to achieve complete molecular remissions, DLI may be combined with prior chemotherapy or concomitant immunomodulatory drugs such as interferon alpha or thalidomide. Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions (DLIs) can induce durable remissions in patients with multiple myeloma (MM). This beneficial graftversus-myeloma (GvM) effect is largely mediated by immunocompetent, allo-reactive donor T cells present in the stem cell grafts, as suggested by the close correlation between the occurrence of graft-versus-host disease (GvHD) and clinical response to DLI.
FA
1,2
In an HLA-identical SCT, allo-reactive donor T cells recognize Minor Histocompatibility antigens (mHags) presented by HLA molecules of the recipient. mHags are immunogenic peptides derived from polymorphic cellular proteins. Of the identified mHags, HA-1 appears to be one of the most interesting minors from a clinical point of view. It is exclusively expressed in hematopoietic cells, induces strong cytotoxic T lymphocyte (CTL) responses and has been associated with graft-versusleukemia (GvL).
3,4 Recently, HA-1 gene transcription was demonstrated in CD138 þ cells isolated from a plasma cell leukemia patient. Furthermore, treatment of an MM patient with DLI from an HLA-identical, HA-1 mismatched donor resulted in a durable remission that correlated with the emergence of circulating HA-1 CTLs.
